Sign Out
Non-squamous non-small cell lung cancer
Adult: In combination with pemetrexed and platinum-containing chemotherapy as 1st-line treatment in patients with tumours which have programmed cell death ligand-1 (PD-L1) expression on ≥50% of tumour cells with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive mutations who have locally advanced non-small cell lung cancer (NSCLC) and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC: 200 mg once every 3 weeks. Continue until disease progression or unacceptable toxicity occurs. Doses are given via IV infusion using an IV line containing a sterile, non-pyrogenic, low-protein binding 0.2 or 0.22 micron in-line or add-on filter, initially over 60 minutes. If tolerated, subsequent infusions may be given over 30 minutes. Dose interruption or discontinuation may be required according to individual safety or tolerability. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Intravenous
Squamous non-small cell lung cancer
Adult: In combination with carboplatin and either paclitaxel or nab-paclitaxel as 1st-line treatment in patients with cases who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC: 200 mg once every 3 weeks. Continue until disease progression or unacceptable toxicity occurs. Doses are given via IV infusion using an IV line containing a sterile, non-pyrogenic, low-protein binding 0.2 or 0.22 micron in-line or add-on filter, initially over 60 minutes. If tolerated, subsequent infusions may be given over 30 minutes. Dose interruption or discontinuation may be required according to individual safety or tolerability. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Intravenous
Locally advanced non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma
Adult: As monotherapy after prior platinum-based therapy (patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab): 200 mg once every 3 weeks. Continue until disease progression or unacceptable toxicity occurs. Doses are given via IV infusion using an IV line containing a sterile, non-pyrogenic, low-protein binding 0.2 or 0.22 micron in-line or add-on filter, initially over 60 minutes. If tolerated, subsequent infusions may be given over 30 minutes. Dose interruption or discontinuation may be required according to individual safety or tolerability. Treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Intravenous
Oesophageal squamous cell carcinoma
Adult: In combination with platinum-based chemotherapy as 1st-line treatment in patients with unresectable, locally advanced or metastatic cases whose tumours expressed PD-L1 with a tumour area positivity (TAP) score of ≥5%; as monotherapy in patients with unresectable, locally advanced or metastatic cases after prior platinum-based chemotherapy: 200 mg once every 3 weeks. Continue until disease progression or unacceptable toxicity occurs. Doses are given via IV infusion using an IV line containing a sterile, non-pyrogenic, low-protein binding 0.2 or 0.22 micron in-line or add-on filter, initially over 60 minutes. If tolerated, subsequent infusions may be given over 30 minutes. Dose interruption or discontinuation may be required according to individual safety or tolerability. Dosing and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Intravenous
Gastric adenocarcinoma, Gastro-oesophageal junction adenocarcinoma
Adult: In combination with platinum and fluoropyrimidine-based chemotherapy as 1st-line treatment in patients with human epidermal growth factor receptor type 2 (HER)-2 negative locally advanced unresectable or metastatic cases whose tumours express PD-L1 with a TAP score of ≥5%: 200 mg once every 3 weeks. Continue until disease progression or unacceptable toxicity occurs. Doses are given via IV infusion using an IV line containing a sterile, non-pyrogenic, low-protein binding 0.2 or 0.22 micron in-line or add-on filter, initially over 60 minutes. If tolerated, subsequent infusions may be given over 30 minutes. Dose interruption or discontinuation may be required according to individual safety or tolerability. Dosing and treatment recommendations may vary among countries and between individual products (refer to specific product guidelines).
Continue with Google